GlassScriptPhysician profile
Richard Maggio
NPI 1205939998
$5,467.61
in general payments reported to CMS, 2019-2025
31 companies · $785 in 2025
The $785 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $259 · 2021: $383 · 2022: $740 · 2023: $1,067 · 2024: $2,028 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,341 · Travel and Lodging: $528 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,340.93 |
| Travel and Lodging | $527.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,485.17 | 2023-2025 | Urolift, Barrigel |
| Janssen Biotech, INC. | $546.43 | 2021-2025 | Erleada, Akeega |
| Astellas Pharma US INC | $495.02 | 2020-2024 | Xtandi, Myrbetriq |
| Procept Biorobotics Corporation | $436.61 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Tolmar, INC. | $366.55 | 2024-2025 | Eligard |
| Bayer Healthcare Pharmaceuticals INC. | $281.25 | 2019-2025 | |
| Abbvie INC. | $258.09 | 2022-2025 | |
| Axonics, INC. | $256.43 | 2023-2024 | Axonics, Bulkamid |
| Merz North America, INC. | $232.63 | 2020-2021 | |
| Urogen Pharma, INC. | $127.71 | 2022-2023 | Jelmyto |
| Progenics Pharmaceuticals, INC. | $116.92 | 2022-2025 | Pylarify |
| Boston Scientific Corporation | $105.09 | 2019-2025 | Axonics, Spaceoar System |
| Sumitomo Pharma America, INC. | $92.42 | 2025 | Orgovyx |
| Endo Pharmaceuticals INC. | $67.70 | 2019-2022 | |
| Urovant Sciences INC | $65.71 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $59.33 | 2024-2025 | Adstiladrin |
| 180 Medical, INC. | $55.93 | 2019-2021 | |
| Olympus America INC. | $55.00 | 2024-2025 | Itind System |
| C. R. Bard, INC. & Subsidiaries | $49.13 | 2019 | |
| Ambu INC. | $46.61 | 2025 | |
| Endo USA, INC. | $46.26 | 2025 | Aveed, Xiaflex |
| Antares Pharma, INC. | $35.75 | 2022 | |
| Galderma Laboratories, L.P. | $30.56 | 2021 | |
| Allergan, INC. | $27.33 | 2021-2022 | |
| Rochester Medical Corporation | $27.13 | 2019-2020 | |
| Dentsply Ih Ab | $23.31 | 2023 | Lofric |
| Myovant Sciences INC. | $19.45 | 2022 | |
| Hollister Incorporated | $18.77 | 2023 | Vapro Plus Pocket, Vapro Pocket |
| Medtronic, INC. | $14.51 | 2023 | Interstim |
| Merck Sharp & Dohme LLC | $13.13 | 2020 | |
| Pfizer INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Maggio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.